Clinical value of fecal calprotectin in determining disease activity of ulcerative colitis

Xiang, Juan; Ouyang, Qi; Li, Guodong; Xiao, Ning

doi:10.3748/wjg.14.53

Cited by 101 publications

(80 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Also should be reiterated that fecal calprotectin cannot distinguish infectious bowel disease from IBD, so appropriate culture studies should always be performed before diagnosing a patient as IBD when the level of fecal calprotectin is high because in both conditions there is heavy invasion by neutrophils ; the main mother cell of calprotectin (9).In the other hand our results showed significant difference between UC patients according to presence or absence of signs of activity with higher values in active disease which simply explained by same concept that during activity there is huge invasion by neutrophils. These results confirm the results of Jun-Ying Xiang et al (22).which concluded that fecal calprotectin concentration in the patients with active UC was significantly higher than that in the inactive UC. They also found a significant difference was also found in the patients with active UC of mild, moderate and severe degrees but they did not determine certain cut off value of fecal calprotectin differentiating active from inactive UC.…”

Section: Figuresupporting

confidence: 83%

Value of Fecal Calprotectin as a Non-Invasive Marker Differentiating Organic From Functional Bowel Diseases

Sheta

Salem

Ismail

et al. 2013

Zagazig University Medical Journal

View full text Add to dashboard Cite

Background: Bowel diseases are very common, most of them are functional not organic in nature but clinicians suffer a lot in differentiating between the two categories especially the management is completely different. The symptoms of functional bowel diseases can be very similar to organic inflammatory bowel diseases like ulcerative colitis. In many cases the definitive diagnosis needs invasive procedures including lower colonoscopy and biopsy for histopathological documentation. Aim of the work: To evaluate the clinical value of fecal calprotectin as a non invasive marker differentiating organic from functional bowel diseases in correlation with endoscopic and histopathological examinations. Subjects and methods: The study included 40 patients, selected to represent 2 groups: group (I) included 20 patients with ulcerative colitis (UC) proved by colonoscopy and histopathology who further subdivided into sub-groups according to activity and site of involvement; and group (II) included 20 patients who had symptoms suggestive of irritable bowel syndrome (IBS) and in whom colonoscopy was found to be normal served as control. All participants were subjected to thorough history taking, physical examination and routine laboratory investigations. Calprotectin in feces was measured using the enzyme-linked immunosorbent assay (ELISA).Results: Fecal calprotectin concentration in the patients with UC was significantly higher than in patients with IBS (Mean values ± SD; 201.7 ± 46.7 μg/g vs, 22.3 ± 10.1 μg/g, P < 0.01). A significant difference was also found in the patients with active UC in comparison to UC patients without sign of activity (Mean values ± SD; 220.2 ± 31.1 μg/g vs, 167.3 ± 23.9 μg/g, P<0.05). The sensitivity of fecal calprotectin at cut off value 195.5 µg/g; as activity marker of UC was 82.2 % while its specificity was 85.7 %., Positive predictive value was 90.1% and negative predictive was 66.6%. Conclusion: Fecal calprotectin can differentiate with great acceptance between organic and functional bowel diseases and can be used as a rational fecal marker for intestinal inflammation in clinical practice. This kind of marker is relatively precise, simple and noninvasive and could give a crude idea about the activity of the lesions.

show abstract

Section: Figuresupporting

confidence: 83%

Value of Fecal Calprotectin as a Non-Invasive Marker Differentiating Organic From Functional Bowel Diseases

Sheta

Salem

Ismail

et al. 2013

Zagazig University Medical Journal

View full text Add to dashboard Cite

show abstract

“…Nevertheless, although fecal calprotectin is not specific it is exceptionally useful in assessment of inflammatory bowel disease. This examination is worth of recommendation especially in children in whom intestinal neoplasm is extremely rare and its non-invasiveness and painlessness causes that it is a promising diagnostic tool, which can supplement the standard methods [7,15,18,27,[30][31][32].…”

Section: Discussionmentioning

confidence: 99%

Fecal Calprotectin as an Activity Marker of Inflammatory Bowel Disease in Children

Krzesiek¹

2015

Adv Clin Exp Med

View full text Add to dashboard Cite

Background. Children constitute 20% of patients with inflammatory bowel diseases (IBD). Still there is a search for a perfect marker for this group of patients which would help in the diagnosis of the disease, in determinating its activity and in monitoring the treatment. Objectives. Evaluate the usefulness of the application of calprotectin measurement in stool samples from children with IBD, as a marker of the severity of inflammation. Material and Methods. We analysed 156 patients: 58 with ulcerative colitis (UC), 67 with Crohn's disease (CD), and 31 from the control group. In all patients the concentration of calprotectin in the sample of feces, markers of inflammation and hemoglobin were measured. Results. Concentration of calprotectin in feces of patients with IBD was above the normal range in all patients with moderate and severe disease and in the majority with mild disease or in remission, but it was normal in all patients from the control group. Conclusions. Elevated concentration of fecal calprotectin (FC) was observed in the majority of patients with IBD, but in none from the control group. The number of patients with elevated FC concentration increased together with the disease activity. FC concentration was higher in patients with severe and moderate disease activity. FC concentration in patients with IBD was associated with the increase of inflammatory markers and decreased haemoglobin. Percentage of laboratory abnormalities in children with Crohn's disease and perianal changes was higher. FC concentration can be a noninvasive marker of disease activity in IBD (Adv Clin Exp Med 2015, 24, 5, 815-822).

show abstract

“…Langhorst et al and Alian et al found a good correlation between the concentrations of fecal lactoferrin, fecal calprotectin, Rachmilewitz Activity Indices, CRP, and blood leukocytes in ulcerative colitis patients (7,42). Also, Xiang et al and Mahmoud et al founded a good correlation between fecal calprotectin, ESR, CRP, and ulcerative colitis activity index in ulcerative colitis patients (8,10). Kilic et al found a significant correlation between TGF-B1 levels and CRP, whereas no significant correlation was established between the other parameters ( blood leucocytes, ESR, fibrinogen level, and platelet count) ( 45 ).On the other hand, Irena et al found a good correlation between TGF-B1 and the concentrations of CRP and platelet count and can be used for evaluation of inflammatory activity in ulcerative colitis and to a lesser extent can also be used for evaluation of inflammatory activity in crohn's disease (41).…”

Section: Resultsmentioning

confidence: 99%

“…In this study, we try to evaluate any relationship that might exist between the mucosal neutrophil infiltration represented by Lactoferrin, calprotectin, TGF-B1, CRP, sedimentation rate, and the ulcerative colitis disease activity represented by Rachmilewitz criteria (8).…”

Section: Resultsmentioning

confidence: 99%

“…Furthermore, it is easy to calculate and increasingly used in clinical practice (7). Colonoscopy and biopsy are useful in the assessment of intestinal mucosal inflammation of patients with ulcerative colitis, but these examinations can be a heavy burden to the patient (8). Several standard markers as erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), acute phase protein e.g., albumin, and platlets are used to aid in diagnosing and monitoring the disease.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Fecal Lactoferrin, Fecal Calprotectin, Transforming growth factor-b1, and CRP in Evaluation of Disease Activity in Egyptian patients With Ulcerative colitis

2017

Int. J. Curr. Res. Med. Sci.

View full text Add to dashboard Cite

Aims: to analyze the usefulness of fecal lactoferrin, fecal calprotectin, transforming growth factor-B1,Endoscopic Activity Index, Clinical Activity Index, C-reactive protein, and blood leucocytes in monitoring disease activity in Egyptian patients with ulcerative colitis. Methods: One hundred and twenty patients with ulcerative colitis were enrolled and scored according to the endoscopic part of the Rachmilewitz Index. Patients and controls: Patients and controls provided fecal and blood samples for measuring Lactoferrin, calprotectin, TGF-B1, CRP, and leucocytes. Results: The values in ulcerative colitis patients (n = 120) compared to controls (n = 30): Fecal lactoferrin: 703.6±657.6 versus7.01±3.9 µg/g, calprotectin: 867.4±561.2 versus 36.3±15.3 μg /g, TGF-B1: 386.9±246.7 versus 5.9±1.8 pg /ml, CRP:19.4±14.7 versus 3.2±0.9 mg/L, blood leucocytes: 11.6±3.8 versus 6.8±1.9 g/L ( for all P< 0.001). Endoscopic disease activity correlated significantly with lactoferrin (Spearman's rank correlation coefficient r =0.949), calprotectin (r = 0.923), TGF-B1 (r = 0.918), Clinical Activity Index (r = 0. 761), CRP (r = 0.851), and blood leucocytes (r = 0.681). Fecal lactoferrin, calprotectin and TGF-B1 levels were significantly lower in ulcerative colitis patients with inactive disease ( endoscopic score 0 -3, Lactoferrin 48.7±24.9 µg/g, calprotectin 81.5 ± 48.8 μg / g, TGF-B1 42.5 ± 36.5 pg/mL , P < 0.001 for both lactoferrin and calprotectin, but P <0.059 for TGF-B1), compared to patients with mild ( score 4 -6, lactoferrin 465.7 ± 217.4 µg/g, calprotectin 420.4 ±244.8 μg/g, TGF-B1 269.6 ± 80.3 pg/mL, P < 0.001 ), moderate ( score 7 -9, lactoferrin 678.7 ± 258.6 µg/g, calprotectin 1074.9 ± 303.5 μg/g, TGF-B1 391.5 ± 56.8 pg/mL, P < 0.001 ), and high disease ( score 10 -12 , lactoferrin 1624.5 ± 327.2 µg/g, calprotectin 1466.5.2 ± 31.5 μg/g, TGF-B1 690.9 ± 160.1 Pg/ mL, P < 0.001). The overall accuracy for detection of histopathological active disease was 96.9 % for fecal lactoferrin, 96.6 for fecal calprotectin, 94.5 % for TGF-B1, 90 % for Endoscopic Activity Index, 87 % for Clinical Activity Index, and 65 % for both blood leucocytes and CRP. Conclusion: Fecal lactoferrin, fecal calprotectin and TGF-B1 correlated significantly with endoscopic disease activity, clinical activity index, CRP, and blood leucocytes. Furthermore, lactoferrin and calprotectin were suitable markers that can differentiate endoscopically and histopathologically inactive from active disease. Also TGF-B1 was used as a useful marker to distinguish mild from moderate and high active disease. Thus, these three biomarkers may be used for monitoring ulcerative colitis activity.

show abstract

Clinical value of fecal calprotectin in determining disease activity of ulcerative colitis

Cited by 101 publications

References 32 publications

Value of Fecal Calprotectin as a Non-Invasive Marker Differentiating Organic From Functional Bowel Diseases

Value of Fecal Calprotectin as a Non-Invasive Marker Differentiating Organic From Functional Bowel Diseases

Fecal Calprotectin as an Activity Marker of Inflammatory Bowel Disease in Children

Fecal Lactoferrin, Fecal Calprotectin, Transforming growth factor-b1, and CRP in Evaluation of Disease Activity in Egyptian patients With Ulcerative colitis

Contact Info

Product

Resources

About